**Many thanks to our donors!**

Both our Science and Policy Programmes, and the dissemination of new information to international organisations, governments and the public, rely exclusively on the generosity of our sponsors. We would like to sincerely thank the Beckley Foundation’s donors for their essential support, and we ask all interested parties to help us develop and expand our programmes of work, both in science and policy.

Any donations, of any amount, are greatly appreciated.

Visit: www.beckleyfoundation.org/donate-2
<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>04</td>
<td>The Beckley Foundation: An Overview</td>
</tr>
<tr>
<td>06</td>
<td>Beckley Foundation Press: Books</td>
</tr>
<tr>
<td>08</td>
<td>Reports</td>
</tr>
<tr>
<td>10</td>
<td>A Selection of Book Chapters by Amanda Feilding</td>
</tr>
<tr>
<td>11</td>
<td>Seminars and Proceedings Documents</td>
</tr>
<tr>
<td>17</td>
<td>Reports and Briefing Papers (2004-2008)</td>
</tr>
<tr>
<td>19</td>
<td>Scientific Publicatons</td>
</tr>
<tr>
<td>25</td>
<td>Scientific Advisory Board</td>
</tr>
<tr>
<td>27</td>
<td>Public Letter</td>
</tr>
</tbody>
</table>
THE BECKLEY FOUNDATION

AN OVERVIEW

Since its creation by Amanda Feilding in 1998, the Beckley Foundation has become renowned for the pioneering work developed through its two strategic aims: on one hand, to reform national and international drug policies by promoting an evidence-based approach to policymaking; and, on the other hand, to increase the understanding brain functioning and consciousness, and to investigate the medical and therapeutic potential of psychoactive substances.

The Foundation’s Policy Programme was created by Amanda as a result of her realising the devastating consequences of the policies of prohibition and the War on Drugs. The Programme aims to provide a rigorous, independent review of current global drug policies and to develop a scientific evidence-base on which to build alternatives. The Programme brings together leading international scientists, politicians and other experts to cast light on the taboo issues around this complex subject and to explore novel policies that are health-oriented, harm-reducing, cost-effective and respectful of individual freedoms. Some of the Programme’s highlights are:

- Over 40 books, reports and briefing papers on global drug policy issues, commissioned, published and distributed by the Beckley Foundation.
- The organisation and hosting of Drugs & Society: A Rational Perspective, a series of policy-focused seminars that bring together leading global policymakers, academics and other experts to discuss national and global policy issues. These seminars, held mainly at the House of Lords in London, have been greatly influential in bringing about drug policy reform since 2002.
- The launch, in 2004, of two influential organisations – (i) the International Drug Policy Consortium (IDPC), and (ii) the International Society for the Study of Drug Policy (ISSDP) – both of which have now become independent.
- In 2011, the landmark publication of Beckley Foundation’s Public Letter calling for a new approach to drug policy, signed by 9 Presidents, 11 Nobel Laureates, and numerous other global notables.
- Our advisory role to the Guatemalan government. In 2012, President Otto Perez Molina invited Amanda to open the Beckley Foundation’s Latin American Chapter, and to advise him on matters related to drug policy. President Molina was the first incumbent head of state to publicly call for global drug policy reform, and also to sign the Foundation’s Public Letter calling for an end to the War on Drugs.

THE BECKLEY FOUNDATION’S PUBLIC LETTER MARKS A WATERSHED MOMENT IN THE HISTORY OF GLOBAL DRUG POLICY REFORM
In parallel with the Policy Programme, the Foundation also runs an extensive **Scientific Programme**, which initiates, funds and co-develops research in collaboration with leading institutions, using the latest developments in neuroscience and brain-imaging technology in order to explore how psychedelics act upon the human brain. The purpose of this research is to increase our scientific understanding of consciousness, and to explore new avenues for the treatment of disease. Amanda has co-authored over 35 scientific articles in high-impact peer-reviewed journals. She has also built up an extensive network of collaborative partnerships with leading scientists and institutions around the world. Selected research collaborations to date include:

- The first studies to use brain imaging technologies, including fMRI and MEG, to examine changes in cerebral blood flow, brain activity and functional connectivity following the administration of psilocybin. Started in 2010 as part of the **Beckley/Imperial Psychedelic Research Programme**, this research has produced new insights into the mechanisms underlying consciousness, and the identification of psilocybin as a potential new treatment for depression. This latter discovery resulted in a substantial grant from the UK government’s **Medical Research Council** to investigate psilocybin in a clinical trial.

- In 2011, a similar study using brain imaging technologies to investigate the effects of MDMA. This study produced important new data, including evidence for the value of this substance as an aid to psychotherapy, in particular to address Post-Traumatic Stress Disorder (PTSD).

- In 2013, the first-ever study to investigate the effects of LSD on the human brain using state of the art brain imaging technologies.

- The first study in modern times to explore the potential of psilocybin as an aid in the treatment of nicotine addiction (collaboration with Johns Hopkins University, USA). The pilot study produced the unparalleled result of an 80% quit rate at 6-month follow-up; substantially exceeding other therapies (typically <65%).

- Some of the earliest studies into the beneficial properties of cannabidiol (CBD), and how cannabis-related harms can be reduced by ensuring a balanced ratio between THC and CBD (collaboration with King's College, London).

---

Our studies with psilocybin have greatly increased the understanding of altered states of consciousness. This visualisation of connectivity between functional areas and networks in the brain under the influence of a) a placebo and b)psilocybin shows how the psychedelic state is associated with a less constrained mode of brain function.

Cannabis Policy: Moving Beyond Stalemate

This book reviews the state of knowledge on the health and psychological effects of cannabis, and its potential for harm in relation to other drugs. It considers patterns and trends in use, the size and character of illicit markets, and current policies under the global prohibition regime.

LSD, My Problem Child and Insights/Outlooks
Albert Hofmann; Translated by Jonathan Ott, Edited by Amanda Feilding, Co-published by the Beckley Foundation Press and Oxford University Press. 2013.

The book gives a new and definitive translation of Albert Hofmann's autobiography, *LSD: My Problem Child*, together with a collection of essays, *Insights/Outlooks*. In it, Hofmann discusses his earlier life and the path that led him to discovering LSD, a drug which had a profound effect on culture and on how science viewed the mind.

Non-Invasive Evaluation of Human Brain Fluid Dynamics and Skull Biomechanics in Relation to Cognitive Functioning
Yuri E Moskalenko, Amanda Feilding and Peter Halvorson, Published by the Beckley Foundation Press. 2010.

This book summarises a fascinating joint research programme which studies cerebral circulation and the cranial system. The research is conducted by Yuri E Moskalenko (Sechenov Institute of Evolutionary Physiology and Biochemistry, Saint Petersburg) in collaboration with Amanda Feilding.

Hofmann’s Elixir: LSD and the New Eleusis
Edited by Amanda Feilding, Published by the Beckley Foundation Press. 2010.

This unique volume collects, for the first time, Hofmann’s more recent essays and lectures, as well as works by contemporary authors. The publication presents a comprehensive overview of Hofmann’s relationship to his controversial creation and reveals his profound mystical outlook.

The Pharmacology of LSD: A Critical Review

This book represents the first-ever comprehensive review of the pharmacological effects of LSD, drawing on data from more than 3000 experimental and clinical studies. LSD has an extraordinary reputation due to the profound effects that it can have on human consciousness, which makes it a valuable research tool, a potential therapeutic agent and a catalyst of individual and social changes.
Psychedelics have been used throughout history for various social and spiritual purposes. Experts suggest that the relationship of humankind with these substances started as early as the Stone Age. Some of these ancient practices have survived into our days.

From the 1960s, psychedelic use leaped into the public sphere in the Americas, Europe and elsewhere when it became associated to the 'hippie' counter-culture. However, a less noticeable phenomenon started two decades before this. Indeed, from the 1940s, a huge wave of studies started investigating these compounds and their effects on the mind. Although of varying scientific rigour, these studies led experts to realise that psychedelic agents had the potential to contribute to our understanding of the psyche and to the treatment of mental health and other conditions.

However, scientific progress came to an abrupt halt in the 1970s, when psychedelic use became perceived as a threat to government and society, leading to an outright ban which was as strict as it was irrational.

In the last two decades, this edifice of censorship has started to crumble, instigated by the work of organisations like ours. We have established collaborations with leading experts to carry out groundbreaking scientific studies and academic research on psychedelics, their mechanisms of action and their potential therapeutic applications. The results advance our understanding of the human psyche and pave the way for these substances’ medical use.

WHY PSYCHEDELIC RESEARCH MATTERS

REVILED FOR DECADES, PSYCHEDELIC RESEARCH IS REGAINING MOMENTUM AND RESULTS ALREADY SHOW GREAT PROMISE FOR THE TREATMENT OF ILLNESSES SUCH AS DEPRESSION, ADDICTION AND ANXIETY.

Psychedelics have been used throughout history for various social and spiritual purposes. Experts suggest that the relationship of humankind with these substances started as early as the Stone Age. Some of these ancient practices have survived into our days.

From the 1960s, psychedelic use leaped into the public sphere in the Americas, Europe and elsewhere when it became associated to the 'hippie' counter-culture. However, a less noticeable phenomenon started two decades before this. Indeed, from the 1940s, a huge wave of studies started investigating these compounds and their effects on the mind. Although of varying scientific rigour, these studies led experts to realise that psychedelic agents had the potential to contribute to our understanding of the psyche and to the treatment of mental health and other conditions.

However, scientific progress came to an abrupt halt in the 1970s, when psychedelic use became perceived as a threat to government and society, leading to an outright ban which was as strict as it was irrational.

In the last two decades, this edifice of censorship has started to crumble, instigated by the work of organisations like ours. We have established collaborations with leading experts to carry out groundbreaking scientific studies and academic research on psychedelics, their mechanisms of action and their potential therapeutic applications. The results advance our understanding of the human psyche and pave the way for these substances’ medical use.
POLICY REPORTS

Licensing and Regulation of the Cannabis Market in England and Wales: Towards a Cost/Benefit Analysis
This pioneering academic report is the most sophisticated investigation to date of the economic consequences of a regulated cannabis market in the UK, indicating that it could be worth as much as £1.25bn a year to the government. The report was commissioned as part of the Beckley Foundation's Global Initiative for Drug Policy Reform.

Paths for Reform: Proposed Options for Alternative Drug Policies in Guatemala
These initial drug policy proposals, produced on the invitation of President Otto Pérez Molina, were presented to the President and his key advisors by Amanda Feilding in January 2013. They were received enthusiastically and the Government has since announced its intention to adopt several of the recommendations, including the regulation of opium poppy cultivation to provide pain-relieving medications for the Guatemalan people.
www.beckleyfoundation.org/Paths-for-Reform.pdf

Illicit Drug Markets and Dimensions of Violence in Guatemala
This report investigates the current illegal drug trends in Guatemala and quantifies the extent of harm and violence which occurs as a result. It also explores the subjects of drugs trafficking, illicit crops, the drugs market, socioeconomic indicators and the law, in order to suggest intelligent proposals for reform.

Roadmaps to Reforming the UN Drug Conventions
Edited by Robin Room; Contributions by Robin Room and Sarah Mackay. 2012.
This pioneering report maps out how the UN Drug Conventions can be amended to increase countries' freedom to adopt drug policies better suited to their individual needs. In particular, the Report details the treaty amendments that would be necessary if a country (or group of countries) wished to experiment with either i) clear decriminalisation or ii) the creation of a regulated market for one or more controlled substances.
www.beckleyfoundation.org/Roadmaps-to-Reform.pdf
The recommendations of the Beckley Foundation’s Global Cannabis Commission included:

• Alternatives to incarceration.
• Decriminalisation.
• Reform, denunciation or dismissal of damaging aspects of UN Drug Treaties.
• Strict regulation.
• Dissemination of reliable information.
• Careful monitoring policy effects.

Cannabis Policy: Moving Beyond Stalemate

The Beckley Foundation’s Global Cannabis Commission was convened by Amanda Feilding in 2006 to bring attention to cannabis, its potential for harm, and how it is currently controlled. The Commission analysed current approaches and identified possible routes forward, including decriminalisation and a regulated legal market. The report also discussed how individual countries can move towards reform. The report was presented at a Beckley Foundation Seminar in 2008, and later co-published with Oxford University Press in 2010.


Our work on cannabis policy raised the subject’s relevance at the international stage, paving the way for reform.
Prohibitionism is a relatively new phenomenon, but the practices it seeks to proscribe and control are as old as human culture itself.

Amanda Feilding
Cannabis and the Psychedelics: Reviewing the UN Drug Conventions
SEMINARS AND PROCEEDINGS DOCUMENTS

Drugs and Society: A Rational Perspective
A series of seminars convened and hosted by Amanda Feilding

Since the establishment of the Beckley Foundation in 1998, Amanda has drawn together high-level academic figures from different disciplines, along with politicians, policy experts and other notables, to discuss key issues related to drug policy and science in a confidential setting.

These meetings, held mostly at the House of Lords, have been extremely influential in educating thought leaders and bringing about change. Amanda and the Beckley Foundation have been a pioneering force in the development of a scientific evidence-base on which to build new drug policies. Indeed, before the work of the Foundation, there had been very little academic analysis of national and international drug policies, or their consequences. The principle that drug policies should be evidence-based is now widely accepted.

Drug Policy Reform (2011)

- Report from the Global Commission on Drug Policy, Paul Volcker, Former Chairman of the US Federal Reserve
- Principles of the Global Commission on Drug Policy, Ruth Dreifuss, Former President of Switzerland
- Effects of Punitive Drug Policies on HIV Epidemics, Kasia Malinowska, Open Society Institute
- Establishing the Conditions for the Debate, Senator Murillo Karam, President, International Affairs Committee, Mexico
- Effects of the War on Drugs in Colombia, Interior Minister German Vargas-Llera, Minister of the Interior, Colombia

Drugs, Poverty and Segregation in South America, Julio Calzada, National Drug Board General Secretary, Uruguay

- Case Studies in the Liberalisation of Drug Policy, Chair Mike Trace, International Drug Policy Consortium
- Drug Use in Portugal – A Background, Dr João Goulão, National Drugs Coordinator, Portugal
- Drug Policy in the Czech Republic, Dr Pavel Bém, Former Drug Policy Coordinator and Member of Parliament, Czech Republic
- Cost-benefit Analysis of Regulation & Taxation of Cannabis, Professor Stephen Pudney, University of Essex
- Reforms to Cannabis Policy in the USA, Tamar Todd, Drug Policy Alliance, USA
- The Challenges in Introducing a Regulated Heroin Treatment, Professor Ambros Uchtenhagen, Chair, Addiction and Public Health Research Foundation, Switzerland
- Swiss Heroin Clinics – Costs & Benefits of Heroin-Assisted Treatment in Switzerland, Dr Barbara Gugger, Medical Doctor to the Berne Opioid Substitution Treatment Service, Switzerland
- UK Opioid Treatment Trial (RIOTT), Professor John Strang, King’s College London; Sarah Byford, Institute of Psychiatry

Tensions between Science and Politics in Drugs Policy, Prof. David Nutt, Imperial College, London

Summary of The Beckley Foundation's Global Cannabis Commission: Cannabis as a Case Study for Wide Reform? Prof. Robin Room, University of Melbourne

How should the International Drug Control System be Evaluated? Dr. David Bewley-Taylor, University of Swansea

The Vienna NGO Committee ‘Beyond 2008’ Initiative, David Turner, Vienna NGO Committee on Narcotic Drugs

The International Drug Policy Consortium Programme, Martin Jelsma, Transnational Institute; Daniel Wolfe, Director, International Harm Reduction Development Program, Open Society Institute

The Latin American ‘Blue Ribbon’ Commission, Rubem Cesar Fernandez, Latin American Initiative on Drugs and Democracy

The UN Review – How is the European Union Preparing? Carel Edwards, Head of the European Commission’s Drug Policy Coordination Unit

What happens next with the UN Review, Mike Trace, Chair of IDPC

Where Can We Go With Cannabis Control? (2008)

Introduction to the Cannabis Commission, Prof. Robin Room, University of Melbourne

A Review of the Health Consequences of Cannabis Use, Prof. Wayne Hall

The Effects of the Current System of Prohibition, Prof. Peter Reuter

A Review of Policy Initiatives of Reforms within the International Prohibition System, Prof. Benedikt Fischer

An Assessment of the Effects of Reforms within the System, Associate Prof. Simon Lenton

Beyond the Conventions, Prof. Robin Room

Conclusions and Recommendations, Prof. Peter Reuter, University of Maryland

A Personal View on the Case for Reforming Cannabis Laws, Rt. Hon. Peter Lilley, MP

Do the More Potent Forms of Cultivated Cannabis Pose Additional Adverse Risks? Prof. Leslie Iversen

Policing Cannabis in Europe, Jan Wiarda, Former Chair of the European Police Chiefs

Net Widening and Stigma in the Policing of Cannabis Laws, Prof. Mike Hough & Prof. Paul Turnbull


Closing Comments, Prof. Colin Blakemore, Ethan Nadelmann and Wayne Hall
UNGASS and the Contribution of Civil Society (2006)

Current Status of Plans for the UNGASS, Alison Crockett, UK Mission to the UNODC

The Work of the Vienna NGO Forum, Michel Perron, Chief Executive, Canadian Centre on Substance Abuse

The Work of the International Drug Policy Consortium, Mike Trace, Chair, IDPC

New Approaches to Source Country Control, Fabrice Poithier, Senlis Council

Rescheduling of Substances within the Conventions, Martin Jelsma, Transnational Institute – Coca Leaf; Katy Swain, Release – Scales of Harm

A Clear Position on Harm Reduction, Daniel Wolfe, International Harm Reduction Development Programme

The Role of the UNODC and INCB, Dave Bewley-Taylor, International Society for the Study of Drug Policy (ISSDP)

OUR 2006 SEMINAR RAISED THE PROFILE OF HARM REDUCTION

Harm reduction is at the core of evidence-based and public-health oriented approaches to drug policy, yet its implementation has been delayed by the punitive policies of prohibition. The seminar denounced the silence from UN agencies in this regard, urging for a coherent and well-resourced harm reduction strategy. The UNODC and other UN bodies have since voiced support for harm reduction.
Global Drug Policy (2005)

Law Enforcement and Supply Reduction, Dr Marcus Roberts, Head of Policy and Parliamentary Unit, MIND; Prof. Francisco Thoumi, Universidad del Rosario, Colombia

Reducing Drug-Related Crime: An overview of the global evidence, Dr Alex Stevens, University of Kent; Prof. Mark Kleiman, UCLA

Reducing Drug-Related Harm to Health, Prof. Gerry Stimson, Executive Director, International Harm Reduction Association; Dr Anindya Chatterjee, UNAIDS

The Medical Potential of Cannabis, Prof. Leslie Iversen, University of Oxford

The Effects of Medical Regulation of Cannabis in the USA, Robert Kampia, Executive Director, Marijuana Policy Project

The Scientific and Therapeutic Potential of Psychedelics, Prof. Dave Nicholls, Purdue University

Cognitive Enhancers: Blurring the Boundaries, Dr John Marsden, Institute of Psychiatry

Strategic Challenges, Dr Andrew Jackson, UK Government Office of Science and Technology

The Science Behind the Future of Recreational Drugs, Prof. David Nutt, University of Bristol

Harm Reduction and the Wider Social Context: Social, ethical and regulatory implications, Prof. Gerry Stimson, Executive Director, International Harm Reduction Association

Why Do People Use Drugs? Prof. Robert MacCoun, UC Berkeley

Is Evidence-Based Drugs Policy Possible? Prof. Mark Kleiman, UCLA

Blurring the Boundaries – The future of cognitive enhancers, Prof. Trevor Robbins, University of Cambridge; Prof. Barbara Sahakian, University of Cambridge

Ethical Dilemmas: Rights and responsibilities, Dr Harald Schmidt, Nuffield Council on Bioethics; Prof. Alastair Campbell, University of Bristol

Closing Discussion, Prof. Colin Blakemore, Executive Director, Medical Research Council; Dr Charles Schuster, Wayne State School of Medicine

We need to look at the potential long-term benefits of substances such as LSD.

Charles Schuster
Director of the National Institute for Drug Abuse (1986 - 1992)

How Can Research Improve Drug Policy? Professor Peter Reuter, University of Maryland
Assessing the Harm of All Social Drugs, Professor Colin Blakemore, Chief Executive, Medical Research Council
Drug Policies to Minimise Aggregate Harm, Professor Mark Kleiman, UCLA
Responding to Drugs – How? Prof. Margaret Hamilton, University of Melbourne
The Truth Has Sometimes to be Suspended, Jan Wiarda, Chairman, European Chiefs of Police

Prospective Drug Policies, Viktor Cherkesov, Chairman, Federal Control of Narcotics of the Russian Federation
The New EU Drug Strategy – How to Create a Meaningful European Policy Framework, Franz Trautmann, Head of International Affairs Unit, Trimbos Institute
No Reason to Make the Same Mistake Twice, Josef Radimecky, National Drug Policy Co-Ordinator, Czech Republic

An Interdisciplinary Perspective on Alcohol and Other Recreational Drugs (2003)

Alcohol and the Brain, Professor David Nutt, University of Bristol
Comparing Cannabis and Alcohol, Professor Leslie Iversen, University of Oxford
Alcohol and Physical Health: A complex equation, Professor Ian Gilmore, Royal Liverpool University Hospital
The Dangers of Alcohol and Costs to the NHS, Professor Colin Drummond, St George’s Hospital Medical School
Treatment Strategies and Individual Differences, Dr Jonathan Chick, University of Edinburgh

The Economics of Alcohol Compared to Other Drugs, Professor Christine Godfrey, University of York
Why Alcohol Is Legal and Other Drugs Are Not, Professor Virginia Berridge, London School of Hygiene and Tropical Medicine
Towards a Pragmatic Policy, Hazel Blears MP, Minister of State for Crime Reduction, Policing and Community Safety
Costs and Benefits of Alcohol and Drugs Policies, Mike Trace
A Scientifically Based Scale of Harm for All Social Drugs, Professor Colin Blakemore, Chief Executive, Medical Research Council

THESE SEMINARS LAUNCHED THE IDEA OF A SCIENTIFIC SCALE OF DRUG HARM AND BENEFITS, WHICH LED TO THE 2007 LANCASTER PAPER BY NUTT, BLAKEMORE, ET AL.

**The Role of Drugs in Society**, Kary Mullis, Nobel Laureate in Chemistry

**Is it Possible to Have Recreational Drugs Which are Relatively Safe?** Prof. Leslie Iversen, University of Oxford

**Are Drugs Here to Stay?** Prof. Cieran Regan, University College Dublin


**Future Drugs: Designing Safer Drugs**, Prof. Gustav Born, William Harvey Research Institute

Drugs and the Brain (2002)

**Brain Mechanisms of Reward and Addiction**, Prof. Trevor Robbins, University of Cambridge

**Cannabis and Ecstasy – Soft Drugs?** Prof. Leslie Iversen, University of Oxford

**Amphetamine and Cocaine – Mechanisms and Hazards**, Prof. Barry J Everitt, University of Cambridge

**Heroin and Related Opiates**, Prof. David J Nutt, University of Bristol

**Psychedelics**, Prof. Mark A Geyer, University of California, San Diego

**How Can We Translate Science into Policy and Action?** Dr Michael Farrell, National Addiction Centre

**The Dutch Policy on Drugs**, Jan Wiarda, Head of Police, The Hague

**Drug Policy in the UK**, Bob Ainsworth MP, Parliamentary Under-Secretary responsible for drug co-ordination

Most of the problems that we currently associate to drugs (high profits, dangerous routes of administration, etc.) are actually a consequence of prohibition.

Kary Mullis
Nobel Prize in Chemistry (1993)
BECKLEY FOUNDATION
REPORTS AND BRIEFING PAPERS (2004-2008)
COMMISSIONED AND EDITED BY AMANDA FEILDING AND MIKE TRACE

Reports

Report 1. Towards a Review of Global Policies on Illegal Drugs
Marcus Roberts, Axel Klein, Mike Trace, May 2004.

Marcus Roberts, Axel Klein, Mike Trace, July 2004.

Report 3. Law Enforcement and Supply Reduction
Marcus Roberts, Axel Klein, Mike Trace, January 2005.

Neil Hunt, Mike Trace, Dave Bewley-Taylor, February 2005.

Alex Stevens, Mike Trace, Dave Bewley-Taylor, June 2005.

Marcus Roberts, Dave Bewley-Taylor, Mike Trace, October 2005.

Report 7. The International Narcotics Control Board: Watchdog or Guardian of the UN Drug Control Conventions?
Dave Bewley-Taylor, Mike Trace, February 2006.

Report 8 Cannabis and Mental Health Responses to the Emerging Evidence
Neil Hunt, Simon Lenton, John Witton, April 2006

Marcus Roberts, Dave Bewley-Taylor, Mike Trace, July 2006.

Report 10. Treatment for Dependent Drug Use: A guide for policymakers
Alex Stevens, Christopher Hallam, Mike Trace, September 2006.

Report 11. The funding of the United Nations Office on Drugs and Crime; an unfinished jigsaw
Dave Bewley-Taylor, Mike Trace, November 2006.

Kate Dolan, Effat Merghati Khoei, Cinzia Brentari, Alex Stevens, June 2007.

Report 13. Recalibrating the Regime: The need for a human rights-based approach to international drug policy
Maureen Meyer with contributions from Coletta Youngers and Dave Bewley-Taylor, February 2008.

Report 14. Understanding Drug Markets And How To Influence Them
Laura Wilson, Alex Stevens. 2008.

Report 15. Drug Markets and Urban Violence: Can tackling one reduce the other?
Dave Bewley-Taylor, Alex Stevens, Pablo Dreyfus, January 2009.

Report 16. The Incarceration of Drug Offenders: An Overview

URBAN VIOLENCE IN DEVELOPING COUNTRIES
IS RELATED TO TRAFFICKING AND SUPPLY, NOT USE.
REPRESSION SHOULD BE, AT THE LEAST, REEVALUATED
Briefing Papers

Briefing 1. Reclassification of Cannabis in the United Kingdom
Mike Trace, Axel Klein, Marcus Roberts, May 2004.

Briefing 2. Drug Policy and the HIV Pandemic in Russia and Ukraine
Axel Klein, Marcus Roberts, Mike Trace, May 2004.

Briefing 3. Drug Consumption Rooms

Briefing 4. Upheavals in the Australian Drug Market: Heroin Drought, Stimulant Flood

Briefing 5. Thailand's 'War on Drugs'

Briefing 6. Decriminalisation of Drugs in Portugal: A Current Overview
Laurence Allen, Mike Trace, Axel Klein.

Briefing 7. Incarceration of Drug Offenders: Costs and Impacts
Dave Bewley-Taylor, Mike Trace, Alex Stevens, June 2005.

Briefing 8. The Rise Of Harm Reduction in the Islamic Republic of Iran
Bijan Nissaramanesh, Mike Trace, Marcus Roberts, July 2005.

Briefing 9. UNAIDS & The Prevention of HIV Infection Through Injecting Drug Use
Mike Trace, Diane Riley, Gerry Stimson, September 2005.

Briefing 10. Drug Policy in India: Compounding Harm?

Mike Trace, Gábor Somogyi, Christopher Hallam, Dave Bewley-Taylor, January 2007.

Briefing 12. The Australian "Heroin Shortage" Six Years On: What, if any, are the Implications for Drug Policy?

Briefing 13. At a Crossroads: Drug Trafficking, Violence and the Mexican State
Maureen Meyer, with contributions from Coletta Youngers and Dave Bewley-Taylor, November 2007.

Briefing 14. The Effects of Decriminalization of Drug Use in Portugal
Caitlin Hughes, Alex Stevens, December 2007.

Briefing 15. Drug Control in Georgia: Drug Testing and the Reduction of Drug Use?

Briefing 16. Ten Years of Plan Colombia: An Analytic Assessment

Given the significant costs of incarceration, it is hard to justify a drug policy approach that prioritises widespread arrest.
BECKLEY FOUNDATION
SCIENTIFIC PUBLICATIONS
INCLUDING A SELECTION OF AMANDA FEILDING’S
SCIENTIFIC PAPERS AND PUBLICATIONS

Since the late 1960s, Amanda Feilding has had a deep interest in studying the changes in cerebral circulation and brain function underlying changed awareness and cognition. In 1978 she wrote a booklet entitled *Blood and Consciousness*.

Within the Beckley Foundation’s Scientific Programme, she has built up a network of collaborative partnerships with leading scientists and institutions around the world. Her research work includes investigation into how psychoactive substances affect consciousness, the benefits and risks associated with their use, and how this knowledge may be used to develop new treatments. Work that Amanda has been carrying out in collaboration with Professor Yuri Moskalenko since 2005 investigates changes in cerebral circulation occurring with age, and work on the development of a new device to monitor cranial compliance.

**Beckley Foundation/Imperial College Psychedelic Research Programme:**
Amanda Feilding’s collaboration with Prof. David Nutt and Dr. Robin Carhart-Harris

**Articles in preparation**

Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Feilding A, Nutt DJ. The paradoxical psychological effects of LSD.


**Published papers**


Collaboration with University College London: Prof. Val Curran and Dr. Celia Morgan


*Beckley Foundation*-sponsored study:


Collaboration with Sant Pau Hospital in Barcelona: Prof. Jordi Riba

Valle M, Maqueda AE, Rabella M, Rodríguez-Pujadas A, Antonijoan RM, Romero S, Alonso JF, Mañanas MA, Friedlander P, Feilding A, Riba J. Inhibition of alpha oscillations through serotonin 2A receptor activation underlies the visual effects of ayahuasca in humans. (submitted to *Neuropsychopharmacology*).


Collaboration with King’s College, Institute of Psychiatry: Dr. Paul Morrison


**Sponsorship of Johns Hopkins Psilocybin in the Treatment of Tobacco Addiction Study**

Prof. Roland Griffiths, Matthew W Johnson et al.


**Collaboration with Freiburg University:**

Prof. Thilo Hinterberger


**Collaboration with the Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences:**

Amanda Feilding in collaboration with Prof. Yuri Moskalenko

Professor Yuri Moskalenko is an internationally recognised expert in the field of cerebral circulation and has written several much-cited books on the subject. This is a selection of publications from their collaboration:


**Original articles:**


**Conference Proceedings:**


**Collaboration with Medizinische Hochschule, Hanover:**
Prof. Torsten Passie


**Collaboration with the University of California at Berkeley:**
Dr. Matthew Baggott


**Early sponsorship of Peter Gasser’s (MAPS Sponsored) LSD/End of Life Anxiety Research**


BECKLEY FOUNDATION SCIENTIFIC FELLOWS

Dr Robin Carhart-Harris, Imperial College London

Mendel Kaelen, Imperial College London
SIR COLIN BLAKEMORE, PH.D., FI.BIOL., F.MED.SCI., HON F.R.C.P., F.R.S.
Former Chief Executive of the Medical Research Council (MRC). Waynflete Professor of Neuroscience and Philosophy at the School of Advanced Study, University of London, and Emeritus Professor of Neuroscience at the University of Oxford. Director of the Oxford Centre for Cognitive Neuroscience. Author of many books including *The Mind Machine, Mechanics of the Mind and Vision: Coding and Efficiency*.

Emeritus Professor of Pharmacology at King's College London University and Professor at the William Harvey Research Institute, St. Bartholomew's Hospital Medical College.

PROF. GORDON CLARIDGE, PH.D., D.SC.
Emeritus Professor of Abnormal Psychology, University of Oxford and Fellow of the British Psychological Society. Author of *The Origins of Mental Illness* and *Schizotypy: Implications for Illness and Health*.

PROF. VALERIE CURRAN, PH.D.
Professor of Psychopharmacology at University College London. Principal Editor of *Psychopharmacology* since 2003.

PROF. MARK GEYER, PH.D.
Distinguished Professor of Psychiatry and Neurosciences and Vice-Chair for Scientific Affairs in Psychiatry at the University of California, San Diego. President of the International Behavioral Neuroscience Society. Scientific Advisor to the European Union’s Innovative Medicine Initiative, and 2011 awardee of Bleuler Prize for Research in Schizophrenias.

PROF. LESTER GRINSPOON, M.D.
Associate Professor Emeritus of Psychiatry at Harvard Medical School. Fellow of the American Association of the Advancement of Science and the American Psychiatric Association Annual Review and the Harvard Mental Health Letter. Author of many books including *Marijuana Reconsidered, Psychedelic Drugs Reconsidered* and *Marijuana: the Forbidden Medicine*.

PROF. LESLIE L. IVERSEN, PH.D., F.R.S.
Chair of the Advisory Council on the Misuse of Drugs, UK, and Visiting Professor of Pharmacology, University of Oxford. Former Director of the MRC Neurochemical Pharmacology Unit, Cambridge. Author of *The Science of Marijuana*.

PROF. YURI E. MOSKALENKO, PH.D.
Head of Laboratory, Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences. Doctor of Sciences, Professor of Physiology, Honour Scientist of The Russian Federation, Academician of International Astronautics Academy.
PROF. DAVID E. NICHOLS, PH.D.
Emeritus Professor of Pharmacology, Purdue University, USA, and Adjunct Professor at the University of North Carolina Chapel Hill, NC. Previously member of numerous NIH, NIMH and NIDA advisory groups. President, co-Founder and Director of the Heffter Research Institute.

PROF. DAVID NUTT, M.D., F.R.C.P., F.R.C.PSYCH., F.MED.SCI.
Head of Neuropsychopharmacology at Imperial College London and Chair of the Independent Scientific Committee on Drugs. President of the European College of Neuropsychopharmacology. Editor of the Journal of Psychopharmacology. Collaborating partner with Amanda Feilding in the Beckley Foundation/Imperial College Psychedelic Research Programme.

PROF. ROGER PERTWEE, D.PHIL., D.SC.
Chair in Neuropharmacology at the University of Aberdeen, Director of Pharmacology for GW Pharmaceuticals, co-chairman of the International Union of Pharmacology (IUPHAR) Subcommittee on Cannabinoid Receptors.

PROF. VILAYANUR RAMACHANDRAN, M.D., PH.D.
Director of the Centre for Brain and Cognition, Distinguished Professor of the Psychology Department and Neuroscience Program, University of California, San Diego. Fellow of All Souls’ College, Oxford, and of the Institute for Advanced Studies in Behavioural Sciences at Stanford. Author of books including Phantoms in the Brain, The Tell-Tale Brain and The Emerging Mind.

PROF. TREVOR ROBBINS, PH.D., C.B.E., F.R.S, F.MED.SCI.
Head of Department of Psychology and Professor of Cognitive Neuroscience at the University of Cambridge. Angharad Dodds John Fellow in Mental Health and Neuropsychiatry and Professor of Cognitive Neuroscience at Downing Cambridge.

PROF. JORDI RIBA, PH.D.
Associate Professor of Pharmacology at the Universidad Autonoma de Barcelona (UAB) and Associate Researcher at the Drug Research Center of the Sant Pau Hospital in Barcelona.

IN MEMORIAM

DR. ALBERT HOFMANN
Discoverer of LSD and founding member of the Beckley Foundation’s Scientific Advisory Board until he passed away in April 2008 at the age of 102.

DR. ALEXANDER SHULGIN, PH.D.
Pharmacologist, chemist and psychoactive drug researcher. Author of PiHKAL, TiHKAL and The Shulgin Index.

DR RONALD SANDISON, M.D.
British psychiatrist and psychotherapist who was a well-known early pioneer in Britain for the clinical use of LSD in psychiatry.
THE GLOBAL WAR ON DRUGS HAS FAILED
IT IS TIME FOR A NEW APPROACH

WE THE UNDERSIGNED call on Governments and
Parliaments to recognise that:

Fifty years after the 1961 UN Single Convention on
Narcotic Drugs was launched, the global war on
drugs has failed, and has had many unintended and
devastating consequences worldwide.

Use of the major controlled drugs has risen, and supply
is cheaper, purer and more available than ever before.
The UN conservatively estimates that there are now 250
million drug users worldwide.

Illicit drugs are now the third most valuable industry in
the world, after food and oil, estimated to be worth over
$350 billion a year, all in the control of criminals.

Fighting the war on drugs costs the world’s taxpayers
incalculable billions each year. Millions of people are
in prison worldwide for drug-related offences, mostly
personal users and small-time dealers.

Corruption amongst law-enforcers and politicians,
especially in producer and transit countries, has spread
as never before, endangering democracy and civil society.
Stability, security and development are threatened by the
fallout from the war on drugs, as are human rights. Tens
of thousands of people die in the drug war each year.

The drug-free world so confidently predicted by
supporters of the war on drugs is further than ever
from attainment. The policies of prohibition create more
harms than they prevent. We must seriously consider
shifting resources away from criminalising tens of
millions of otherwise law abiding citizens, and move
towards an approach based on health, harm-reduction,
cost-effectiveness and respect for human rights. Evidence
consistently shows that these health-based approaches
deliver better results than criminalisation.

Improving our drug policies is one of the key policy
challenges of our time. It is time for world leaders to
fundamentally review their strategies in response to the
drug phenomenon.

At the root of current policies lies the 1961 UN Single
Convention on Narcotic Drugs. It is time to re-examine
this treaty which imposes a ‘one-size-fits-all’ solution,
in order to allow individual countries the freedom to
explore drug policies that better suit their domestic
needs.

As the production, demand and use of drugs cannot be
eradicated, new ways must be found to minimise harms,
and new policies, based on scientific evidence, must be
explored.

Let us break the taboo on debate and reform. The time
for action is now.

Yours faithfully,

President Juan Manuel Santos
President of the Republic of Colombia

President Otto Pérez Molina
President of the Republic of Guatemala

President Jimmy Carter
Former President of the United States.
Nobel Prize winner

President Fernando H. Cardoso
Former President of Brazil

President César Gaviria
Former President of Colombia

President Vicente Fox
Former President of Mexico

President Ruth Dreifuss
Former President of Switzerland

President Lech Wałęsa
Former President of Poland, Nobel Prize
winner

President Alexander Kwaśniewski
Former President of Poland

George P. Schultz
Former US Secretary of State

Desmond Tutu
Archbishop. Nobel Prize winner

Mario Vargas Llosa
Writer. Nobel Prize winner

Dr. Kary Mullis
Chemist. Nobel Prize winner

Professor Sir Harold Kroto
Chemist. Nobel Prize winner

Professor John Polanyi
Chemist. Nobel Prize winner

Professor Kenneth Arrow
Economist. Nobel Prize winner

Professor Thomas C. Schelling
Economist. Nobel Prize winner

Professor Sir Peter Mansfield
Physicist. Nobel Prize winner

Professor Sir Anthony Leggett
Physicist. Nobel Prize winner

Professor Martin L. Perl
Physicist. Nobel Prize winner

Wisława Szymborska
Poet. Nobel Prize winner

Sir Richard Branson
Entrepreneur, founder of Virgin Group

Sting
Musician and actor

Yoko Ono
Musician and artist

Carlos Fuentes
Novelist and essayist

Gilberto Gil
Former Minister of Culture, Brazil

Sean Parker
Founding President of Facebook, Spotify

Thorvald Stoltenberg
Former UN High Commissioner, Refugees

Louise Arbour, CC, GOQ
Former UN High Commissioner, Human
Rights

Javier Solana, KOGF, KCMG
Former Secretary General, EU Council

Professor Noam Chomsky
Professor of Linguistics & Philosophy, MIT

Amanda Feilding
Director, the Beckley Foundation

To add your name to our list of signatories please visit our website: www.beckleyfoundation.org